AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation

Journal of Molecular and Cellular Cardiology

Volumn 91, Issue , 2016, Pages 188-200

  Daskalopoulos, Evangelos P ^a,b   Dufeys, Cécile ^a   Bertrand, Luc ^a   Beauloye, Christophe ^a,c   Horman, Sandrine ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Cardiovascular Research Institute   (Greece)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

AMPK; Cardiac fibrosis; Cardiac metabolism; Cardiac remodeling; Hypertrophy; Ischemia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENYLATE KINASE; ADIPONECTIN; ADRENERGIC RECEPTOR; BERBERINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; RIBONUCLEOTIDE; SCLEROPROTEIN; STILBENE DERIVATIVE;

AGING; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HEART VOLUME; HUMAN; INTRACELLULAR SIGNALING; METABOLIC DISORDER; METABOLIC REGULATION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; WNT SIGNALING PATHWAY; ANALOGS AND DERIVATIVES; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMEGALY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; SIGNAL TRANSDUCTION; WOUND HEALING;

AGING; AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; BERBERINE; CARDIOMEGALY; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; METFORMIN; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; STILBENES; THIAZOLIDINEDIONES; WOUND HEALING;

EID: 84961319891     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.01.001     Document Type: Review

References (202)

1. Carlson C.A., Kim K.H. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J. Biol. Chem. 1973, 248:378-380.
2. Beauloye C., Bertrand L., Horman S., Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc. Res. 2011, 90:224-233.
3. Park C.S., Bang B.R., Kwon H.S., Moon K.A., Kim T.B., Lee K.Y., et al. Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase. Biochem. Pharmacol. 2012, 84:1660-1670.
4. Kim H., Moon S.Y., Kim J.S., Baek C.H., Kim M., Min J.Y., et al. Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis. Am. J. Physiol. Ren. Physiol. 2015, 308:F226-F236.
5. Lim J.Y., Oh M.A., Kim W.H., Sohn H.Y., Park S.I. AMP-activated protein kinase inhibits TGF-beta-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. J. Cell. Physiol. 2012, 227:1081-1089.
6. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214:199-210.
7. Rockey D.C., Bell P.D., Hill J.A. Fibrosis-a common pathway to organ injury and failure. N. Engl. J. Med. 2015, 373:96.
8. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ. Res. 2009, 105:1164-1176.
9. Camelliti P., Borg T.K., Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 2005, 65:40-51.
10. Rienks M., Papageorgiou A.P., Frangogiannis N.G., Heymans S. Myocardial extracellular matrix: an ever-changing and diverse entity. Circ. Res. 2014, 114:872-888.
11. Daskalopoulos E.P., Hermans K.C.M., van Delft L., Altara R., Blankesteijn W.M. Inflammation in Heart Failure 2014, Academic Press. first ed.
12. Weber K.T., Pick R., Jalil J.E., Janicki J.S., Carroll E.P. Patterns of myocardial fibrosis. J. Mol. Cell. Cardiol. 1989, 21(Suppl. 5):121-131.
13. Masci P.G., Doulaptsis C., Bertella E., Del Torto A., Symons R., Pontone G., et al. Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure. Circ. Heart Fail. 2014, 7:448-456.
14. Daskalopoulos E.P., Hermans K.C., Blankesteijn W.M. Cardiac (myo)fibroblast: novel strategies for its targeting following myocardial infarction. Curr. Pharm. Des. 2014, 20:1987-2002.
15. Small E.M., Thatcher J.E., Sutherland L.B., Kinoshita H., Gerard R.D., Richardson J.A., et al. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ. Res. 2010, 107:294-304.
16. Leslie K.O., Taatjes D.J., J S., M vT., RB L. Cardiac myofibroblasts express alpha smooth muscle actin during right ventricular pressure overload in the rabbit. Am. J. Pathol. 1991, 139:207-216.
17. Fowlkes V., Clark J., Fix C., Law B.A., Morales M.O., Qiao X., et al. Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts. Life Sci. 2013, 92:669-676.
18. Szardien S., Nef H.M., Troidl C., Willmer M., Voss S., Liebetrau C., et al. Bone marrow-derived cells contribute to cell turnover in aging murine hearts. Int. J. Mol. Med. 2012, 30:283-287.
19. Lech M., Anders H.J. Macrophages and fibrosis: how resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair. Biochim. Biophys. Acta 1832, 2013:989-997.
20. Moore J.P., Vinh A., Tuck K.L., Sakkal S., Krishnan S.M., Chan C.T., et al. M2 macrophage accumulation in the aortic wall during angiotensin II infusion in mice is associated with fibrosis, elastin loss and elevated blood pressure. Am. J. Physiol. Heart Circ. Physiol. 2015, (ajpheart 00821 2014).
21. Shivshankar P., Halade G.V., Calhoun C., Escobar G.P., Mehr A.J., Jimenez F., et al. Caveolin-1 deletion exacerbates cardiac interstitial fibrosis by promoting M2 macrophage activation in mice after myocardial infarction. J. Mol. Cell. Cardiol. 2014, 76:84-93.
22. Lauriol J., Keith K., Jaffre F., Couvillon A., Saci A., Goonasekera S.A., et al. RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis. Sci. Signal. 2014, 7:ra100.
23. Gogiraju R., Xu X., Bochenek M.L., Steinbrecher J.H., Lehnart S.E., Wenzel P., et al. Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice. J. Am. Heart Assoc. 2015, 4.
24. Chu P.Y., Mariani J., Finch S., McMullen J.R., Sadoshima J., Marshall T., et al. Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am. J. Pathol. 2010, 176:1735-1742.
25. Liao C.H., Akazawa H., Tamagawa M., Ito K., Yasuda N., Kudo Y., et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J. Clin. Invest. 2010, 120:242-253.
26. Kong P., Christia P., Frangogiannis N.G. The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 2014, 71:549-574.
27. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 2003, 108:1395-1403.
28. Bowers S.L., Banerjee I., Baudino T.A. The extracellular matrix: at the center of it all. J. Mol. Cell. Cardiol. 2010, 48:474-482.
29. Weber K.T. From inflammation to fibrosis: a stiff stretch of highway. Hypertension 2004, 43:716-719.
30. Badenhorst D., Maseko M., Tsotetsi O.J., Naidoo A., Brooksbank R., Norton G.R., et al. Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. Cardiovasc. Res. 2003, 57:632-641.
31. Van Aelst L.N., Voss S., Carai P., Van Leeuwen R., Vanhoutte D., Sanders-van Wijk S., et al. Osteoglycin prevents cardiac dilatation and dysfunction after myocardial infarction through infarct collagen strengthening. Circ. Res. 2015, 116:425-436.
32. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 2007, 87:1285-1342.
33. Van Linthout S., Seeland U., Riad A., Eckhardt O., Hohl M., Dhayat N., et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res. Cardiol. 2008, 103:319-327.
34. Chiao Y.A., Ramirez T.A., Zamilpa R., Okoronkwo S.M., Dai Q., Zhang J., et al. Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc. Res. 2012, 96:444-455.
35. Fan D., Takawale A., Basu R., Patel V., Lee J., Kandalam V., et al. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovasc. Res. 2014, 103:268-280.
36. Viollet B., Athea Y., Mounier R., Guigas B., Zarrinpashneh E., Horman S., et al. AMPK: lessons from transgenic and knockout animals. Front. Biosci. 2009, 14:19-44.
37. Li J., Coven D.L., Miller E.J., Hu X., Young M.E., Carling D., et al. Activation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heart. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1927-H1934.
38. Pinter K., Grignani R.T., Czibik G., Farza H., Watkins H., Redwood C. Embryonic expression of AMPK gamma subunits and the identification of a novel gamma2 transcript variant in adult heart. J. Mol. Cell. Cardiol. 2012, 53:342-349.
39. Kim A.S., Miller E.J., Wright T.M., Li J., Qi D., Atsina K., et al. A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 2011, 51:24-32.
40. Sakamoto K., Zarrinpashneh E., Budas G.R., Pouleur A.C., Dutta A., Prescott A.R., et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E780-E788.
41. Hardie D.G., Ashford M.L. AMPK: regulating energy balance at the cellular and whole body levels. Physiology (Bethesda) 2014, 29:99-107.
42. Gowans G.J., Hawley S.A., Ross F.A., Hardie D.G. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab. 2013, 18:556-566.
43. Qi D., Atsina K., Qu L., Hu X., Wu X., Xu B., et al. The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury. J. Clin. Invest. 2014, 124:3540-3550.
44. Xie M., Zhang D., Dyck J.R., Li Y., Zhang H., Morishima M., et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17378-17383.
45. Horman S., Vertommen D., Heath R., Neumann D., Mouton V., Woods A., et al. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J. Biol. Chem. 2006, 281:5335-5340.
46. Lin Y.Y., Kiihl S., Suhail Y., Liu S.Y., Chou Y.H., Kuang Z., et al. Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK. Nature 2012, 482:251-255.
47. Shao D., Oka S., Liu T., Zhai P., Ago T., Sciarretta S., et al. A redox-dependent mechanism for regulation of AMPK activation by Thioredoxin1 during energy starvation. Cell Metab. 2014, 19:232-245.
48. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
49. Xiao B., Sanders M.J., Carmena D., Bright N.J., Haire L.F., Underwood E., et al. Structural basis of AMPK regulation by small molecule activators. Nat. Commun. 2013, 4:3017.
50. Hunter R.W., Foretz M., Bultot L., Fullerton M.D., Deak M., Ross F.A., et al. Mechanism of action of compound-13: an alpha1-selective small molecule activator of AMPK. Chem. Biol. 2014, 21:866-879.
51. Hawley S.A., Ross F.A., Chevtzoff C., Green K.A., Evans A., Fogarty S., et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010, 11:554-565.
52. Xu M., Zhao Y.T., Song Y., Hao T.P., Lu Z.Z., Han Q.D., et al. Alpha1-adrenergic receptors activate AMP-activated protein kinase in rat hearts. Sheng Li Xue Bao 2007, 59:175-182.
53. Jaswal J.S., Lund C.R., Keung W., Beker D.L., Rebeyka I.M., Lopaschuk G.D. Isoproterenol stimulates 5'-AMP-activated protein kinase and fatty acid oxidation in neonatal hearts. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H1135-H1145.
54. Saeedi R., Saran V.V., Wu S.S., Kume E.S., Paulson K., Chan A.P., et al. AMP-activated protein kinase influences metabolic remodeling in H9c2 cells hypertrophied by arginine vasopressin. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1822-H1832.
55. Horman S., Morel N., Vertommen D., Hussain N., Neumann D., Beauloye C., et al. AMP-activated protein kinase phosphorylates and desensitizes smooth muscle myosin light chain kinase. J. Biol. Chem. 2008, 283:18505-18512.
56. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 2005, 11:1096-1103.
57. Kambara T., Shibata R., Ohashi K., Matsuo K., Hiramatsu-Ito M., Enomoto T., et al. C1q/tumor necrosis factor-related protein 9 protects against acute myocardial injury through an adiponectin receptor I-AMPK-dependent mechanism. Mol. Cell. Biol. 2015, 35:2173-2185.
58. Kataoka Y., Shibata R., Ohashi K., Kambara T., Enomoto T., Uemura Y., et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms. J. Am. Coll. Cardiol. 2014, 63:2722-2733.
59. Li J., Qi D., Cheng H., Hu X., Miller E.J., Wu X., et al. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:16133-16138.
60. Miller E.J., Li J., Leng L., McDonald C., Atsumi T., Bucala R., et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008, 451:578-582.
61. Ogura Y., Ouchi N., Ohashi K., Shibata R., Kataoka Y., Kambara T., et al. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation 2012, 126:1728-1738.
62. Horman S., Beauloye C., Vanoverschelde J.L., Bertrand L. AMP-activated protein kinase in the control of cardiac metabolism and remodeling. Curr. Heart Fail. Rep. 2012, 9:164-173.
63. Matsui Y., Takagi H., Qu X., Abdellatif M., Sakoda H., Asano T., et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and beclin 1 in mediating autophagy. Circ. Res. 2007, 100:914-922.
64. Takagi H., Matsui Y., Hirotani S., Sakoda H., Asano T., Sadoshima J. AMPK mediates autophagy during myocardial ischemia in vivo. Autophagy 2007, 3:405-407.
65. Terai K., Hiramoto Y., Masaki M., Sugiyama S., Kuroda T., Hori M., et al. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol. Cell. Biol. 2005, 25:9554-9575.
66. Song P., Zou M.H. Regulation of NAD(P)H oxidases by AMPK in cardiovascular systems. Free Radic. Biol. Med. 2012, 52:1607-1619.
67. Timmermans A.D., Balteau M., Gelinas R., Renguet E., Ginion A., de Meester C., et al. A-769662 potentiates the effect of other AMP-activated protein kinase activators on cardiac glucose uptake. Am. J. Physiol. Heart Circ. Physiol. 2014, 306:H1619-H1630.
68. Zordoky B.N., Nagendran J., Pulinilkunnil T., Kienesberger P.C., Masson G., Waller T.J., et al. AMPK-dependent inhibitory phosphorylation of ACC is not essential for maintaining myocardial fatty acid oxidation. Circ. Res. 2014, 115:518-524.
69. Russell R.R., Li J., Coven D.L., Pypaert M., Zechner C., Palmeri M., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 2004, 114:495-503.
70. Wang Y., Gao E., Tao L., Lau W.B., Yuan Y., Goldstein B.J., et al. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation 2009, 119:835-844.
71. Zarrinpashneh E., Carjaval K., Beauloye C., Ginion A., Mateo P., Pouleur A.C., et al. Role of the alpha2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2875-H2883.
72. Noppe G., Dufeys C., Buchlin P., Marquet N., Castanares-Zapatero D., Balteau M., et al. Reduced scar maturation and contractility lead to exaggerated left ventricular dilation after myocardial infarction in mice lacking AMPKalpha1. J. Mol. Cell. Cardiol. 2014, 74:32-43.
73. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 2003, 65:45-79.
74. Zarrinpashneh E., Beauloye C., Ginion A., Pouleur A.C., Havaux X., Hue L., et al. AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol. Biochem. Biophys. Res. Commun. 2008, 376:677-681.
75. Tian R., Musi N., D'Agostino J., Hirshman M.F., Goodyear L.J. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001, 104:1664-1669.
76. Li H.L., Yin R., Chen D., Liu D., Wang D., Yang Q., et al. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J. Cell. Biochem. 2007, 100:1086-1099.
77. Zhang P., Hu X., Xu X., Fassett J., Zhu G., Viollet B., et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008, 52:918-924.
78. Zong J., Deng W., Zhou H., Bian Z.Y., Dai J., Yuan Y., et al. 3,3'-Diindolylmethane protects against cardiac hypertrophy via 5'-adenosine monophosphate-activated protein kinase-alpha2. PLoS ONE 2013, 8.
79. Ma X., Fu Y., Xiao H., Song Y., Chen R., Shen J., et al. Cardiac fibrosis alleviated by exercise training is AMPK-dependent. PLoS ONE 2015, 10.
80. Alesutan I., Voelkl J., Stockigt F., Mia S., Feger M., Primessnig U., et al. AMP-activated protein kinase alpha1 regulates cardiac gap junction protein connexin 43 and electrical remodeling following pressure overload. Cell. Physiol. Biochem. 2015, 35:406-418.
81. Horgan S., Watson C., Glezeva N., Baugh J. Murine models of diastolic dysfunction and heart failure with preserved ejection fraction. J. Card. Fail. 2014, 20:984-995.
82. Xing Y., Musi N., Fujii N., Zou L., Luptak I., Hirshman M.F., et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J. Biol. Chem. 2003, 278:28372-28377.
83. Sung M.M., Zordoky B.N., Bujak A.L., Lally J.S., Fung D., Young M.E., et al. AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism. Cardiovasc. Res. 2015, 107:235-245.
84. Sakamoto A., Hongo M., Furuta K., Saito K., Nagai R., Ishizaka N. Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension. Int. J. Cardiol. 2013, 167:409-415.
85. Kato M.F., Shibata R., Obata K., Miyachi M., Yazawa H., Tsuboi K., et al. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J. Hypertens. 2008, 26:1669-1676.
86. Sung M.M., Das S.K., Levasseur J., Byrne N.J., Fung D., Kim T.T., et al. Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism. Circ. Heart Fail. 2015, 8:128-137.
87. Matsuura N., Asano C., Nagasawa K., Ito S., Sano Y., Minagawa Y., et al. Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome. Int. J. Cardiol. 2015, 179:360-369.
88. Hermida N., Markl A., Hamelet J., Van Assche T., Vanderper A., Herijgers P., et al. HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. Cardiovasc. Res. 2013, 99:44-54.
89. Cieslik K.A., Taffet G.E., Crawford J.R., Trial J., Mejia Osuna P., Entman M.L. AICAR-dependent AMPK activation improves scar formation in the aged heart in a murine model of reperfused myocardial infarction. J. Mol. Cell. Cardiol. 2013, 63:26-36.
90. Andersson C., Sogaard P., Hoffmann S., Hansen P.R., Vaag A., Major-Pedersen A., et al. Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes. Eur. J. Endocrinol. 2010, 163:593-599.
91. Tsuji T., Mizushige K., Noma T., Murakami K., Ohmori K., Miyatake A., et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J. Cardiovasc. Pharmacol. 2001, 38:868-874.
92. Ingwall J.S., Weiss R.G. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ. Res. 2004, 95:135-145.
93. Kim T.T., Dyck J.R. Is AMPK the savior of the failing heart?. Trends Endocrinol. Metab. 2015, 26:40-48.
94. Ruderman N.B., Carling D., Prentki M., Cacicedo J.M. AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest. 2013, 123:2764-2772.
95. Falcao-Pires I., Leite-Moreira A.F. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail. Rev. 2012, 17:325-344.
96. Lee J.E., Yi C.O., Jeon B.T., Shin H.J., Kim S.K., Jung T.S., et al. Alpha-lipoic acid attenuates cardiac fibrosis in Otsuka Long-Evans Tokushima fatty rats. Cardiovasc. Diabetol. 2012, 11:111.
97. He C., Zhu H., Li H., Zou M.H., Xie Z. Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes. Diabetes 2013, 62:1270-1281.
98. van Bilsen M., Daniels A., Brouwers O., Janssen B.J., Derks W.J., Brouns A.E., et al. Hypertension is a conditional factor for the development of cardiac hypertrophy in type 2 diabetic mice. PLoS ONE 2014, 9.
99. Strait J.B., Lakatta E.G. Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail. Clin. 2012, 8:143-164.
100. Zhang Y., Mi S.L., Hu N., Doser T.A., Sun A., Ge J., et al. Mitochondrial aldehyde dehydrogenase 2 accentuates aging-induced cardiac remodeling and contractile dysfunction: role of AMPK, Sirt1, and mitochondrial function. Free Radic. Biol. Med. 2014, 71:208-220.
101. Hofmann J.W., Zhao X., De Cecco M., Peterson A.L., Pagliaroli L., Manivannan J., et al. Reduced expression of MYC increases longevity and enhances healthspan. Cell 2015, 160:477-488.
102. Dobaczewski M., Chen W., Frangogiannis N.G. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J. Mol. Cell. Cardiol. 2011, 51:600-606.
103. Desmouliere A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 1993, 122:103-111.
104. Mishra R., Cool B.L., Laderoute K.R., Foretz M., Viollet B., Simonson M.S. AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J. Biol. Chem. 2008, 283:10461-10469.
105. Wu D., Lei H., Wang J.Y., Zhang C.L., Feng H., Fu F.Y., et al. CTRP3 attenuates post-infarct cardiac fibrosis by targeting Smad3 activation and inhibiting myofibroblast differentiation. J. Mol. Med. (Berl) 2015.
106. Brilla C.G., Pick R., Tan L.B., Janicki J.S., Weber K.T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. 1990, 67:1355-1364.
107. Brilla C.G., Zhou G., Matsubara L., Weber K.T. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J. Mol. Cell. Cardiol. 1994, 26:809-820.
108. Hernandez J.S., Barreto-Torres G., Kuznetsov A.V., Khuchua Z., Javadov S. Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria. J. Cell. Mol. Med. 2014, 18:709-720.
109. Murca T.M., Moraes P.L., Capuruco C.A., Santos S.H., Melo M.B., Santos R.A., et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul. Pept. 2012, 177:107-115.
110. Fujita K., Maeda N., Sonoda M., Ohashi K., Hibuse T., Nishizawa H., et al. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler. Thromb. Vasc. Biol. 2008, 28:863-870.
111. Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20:781-810.
112. Daskalopoulos E.P., Hermans K.C., Janssen B.J., Matthijs B.W. Targeting the Wnt/frizzled signaling pathway after myocardial infarction: a new tool in the therapeutic toolbox?. Trends Cardiovasc. Med. 2013, 23:121-127.
113. Sklepkiewicz P., Shiomi T., Kaur R., Sun J., Kwon S., Mercer B., et al. Loss of secreted frizzled-related protein-1 leads to deterioration of cardiac function in mice and plays a role in human cardiomyopathy. Circ. Heart Fail. 2015, 8:362-372.
114. He W., Zhang L., Ni A., Zhang Z., Mirotsou M., Mao L., et al. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21110-21115.
115. Zhang M., Hagenmueller M., Riffel J.H., Kreusser M.M., Bernhold E., Fan J., et al. Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy. Hypertension 2015, 65:335-344.
116. Akhmetshina A., Palumbo K., Dees C., Bergmann C., Venalis P., Zerr P., et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat. Commun. 2012, 3:735.
117. Zhao J., Yue W., Zhu M.J., Sreejayan N., Du M. AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552. Biochem. Biophys. Res. Commun. 2010, 395:146-151.
118. Takatani T., Minagawa M., Takatani R., Kinoshita K., Kohno Y. AMP-activated protein kinase attenuates Wnt/beta-catenin signaling in human osteoblastic Saos-2 cells. Mol. Cell. Endocrinol. 2011, 339:114-119.
119. Lee H., Kang R., Bae S., Yoon Y. AICAR, an activator of AMPK, inhibits adipogenesis via the WNT/beta-catenin pathway in 3T3-L1 adipocytes. Int. J. Mol. Med. 2011, 28:65-71.
120. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
121. Murdoch C.E., Chaubey S., Zeng L., Yu B., Ivetic A., Walker S.J., et al. Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J. Am. Coll. Cardiol. 2014, 63:2734-2741.
122. Lew W.Y., Bayna E., Dalle Molle E., Contu R., Condorelli G., Tang T. Myocardial fibrosis induced by exposure to subclinical lipopolysaccharide is associated with decreased miR-29c and enhanced NOX2 expression in mice. PLoS ONE 2014, 9.
123. Chan E.C., Peshavariya H.M., Liu G.S., Jiang F., Lim S.Y., Dusting G.J. Nox4 modulates collagen production stimulated by transforming growth factor beta1 in vivo and in vitro. Biochem. Biophys. Res. Commun. 2013, 430:918-925.
124. Schuhmacher S., Foretz M., Knorr M., Jansen T., Hortmann M., Wenzel P., et al. Alpha1amp-activated protein kinase preserves endothelial function during chronic angiotensin II treatment by limiting Nox2 upregulation. Arterioscler. Thromb. Vasc. Biol. 2011, 31:560-566.
125. Balteau M., Van Steenbergen A., Timmermans A.D., Dessy C., Behets-Wydemans G., Tajeddine N., et al. AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2014, 307:H1120-H1133.
126. Li Q., Wang Y., Sun S.Z., Tian Y.J., Liu M.H. Effects of benazepril on cardiac fibrosis in STZ-induced diabetic rats. Acta Cardiol. 2010, 65:431-439.
127. Seeland U., Schaffer A., Selejan S., Hohl M., Reil J.C., Muller P., et al. Effects of AT1- and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic mice. Eur. J. Clin. Investig. 2009, 39:851-859.
128. Zhi H., Luptak I., Alreja G., Shi J., Guan J., Metes-Kosik N., et al. Effects of direct renin inhibition on myocardial fibrosis and cardiac fibroblast function. PLoS ONE 2013, 8.
129. Tanaka-Esposito C., Varahan S., Jeyaraj D., Lu Y., Stambler B.S. Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. J. Cardiovasc. Electrophysiol. 2014, 25:537-544.
130. AC S.e.S., KD S., AJ F., MM T. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br. J. Pharmacol. 2013, 169:477-492.
131. Der Sarkissian S., Grobe J.L., Yuan L., Narielwala D.R., Walter G.A., Katovich M.J., et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008, 51:712-718.
132. Grobe J.L., Mecca A.P., Lingis M., Shenoy V., Bolton T.A., Machado J.M., et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H736-H742.
133. Gundewar S., Calvert J.W., Jha S., Toedt-Pingel I., Ji S.Y., Nunez D., et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ. Res. 2009, 104:403-411.
134. Solskov L., Lofgren B., Kristiansen S.B., Jessen N., Pold R., Nielsen T.T., et al. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24hours after administration. Basic Clin. Pharmacol. Toxicol. 2008, 103:82-87.
135. Chan A.Y., Soltys C.L., Young M.E., Proud C.G., Dyck J.R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem. 2004, 279:32771-32779.
136. Bai J., Zhang N., Hua Y., Wang B., Ling L., Ferro A., et al. Metformin inhibits angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts. PLoS ONE 2013, 8.
137. Yin M., van der Horst I.C., van Melle J.P., Qian C., van Gilst W.H., Sillje H.H., et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H459-H468.
138. Sasaki H., Asanuma H., Fujita M., Takahama H., Wakeno M., Ito S., et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009, 119:2568-2577.
139. Xiao H., Ma X., Feng W., Fu Y., Lu Z., Xu M., et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc. Res. 2010, 87:504-513.
140. Brunmair B., Staniek K., Gras F., Scharf N., Althaym A., Clara R., et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 2004, 53:1052-1059.
141. Li P., Shibata R., Unno K., Shimano M., Furukawa M., Ohashi T., et al. Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone. Hypertension 2010, 55:69-75.
142. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356:2457-2471.
143. Noyan-Ashraf M.H., Momen M.A., Ban K., Sadi A.M., Zhou Y.Q., Riazi A.M., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
144. Noyan-Ashraf M.H., Shikatani E.A., Schuiki I., Mukovozov I., Wu J., Li R.K., et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 2013, 127:74-85.
145. Hirakawa H., Zempo H., Ogawa M., Watanabe R., Suzuki J., Akazawa H., et al. A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. PLoS ONE 2015, 10.
146. Koibuchi N., Hasegawa Y., Katayama T., Toyama K., Uekawa K., Sueta D., et al. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc. Diabetol. 2014, 13:157.
147. Lenski M., Kazakov A., Marx N., Bohm M., Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J. Mol. Cell. Cardiol. 2011, 51:906-918.
148. Al-masri I.M., Mohammad M.K., Tahaa M.O. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J. Enzyme Inhib. Med. Chem. 2009, 24:1061-1066.
149. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
150. Li Y., Wang P., Zhuang Y., Lin H., Li Y., Liu L., et al. Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes. FEBS Lett. 2011, 585:1735-1740.
151. Li M.H., Zhang Y.J., Yu Y.H., Yang S.H., Iqbal J., Mi Q.Y., et al. Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. Eur. J. Pharmacol. 2014, 728:67-76.
152. Zhang Y.J., Yang S.H., Li M.H., Iqbal J., Bourantas C.V., Mi Q.Y., et al. Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: role of autophagy. Clin. Exp. Pharmacol. Physiol. 2014, 41:995-1002.
153. Kiriazis H., Wang K., Xu Q., Gao X.M., Ming Z., Su Y., et al. Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis. Br. J. Pharmacol. 2008, 153:684-692.
154. Ravindranathan M.P., Jenkins B., Haider B., Regan T.J. Effects of beta-adrenergic inhibition on scar formation after myocardial infarction. Am. Heart J. 1984, 108:25-30.
155. Pulinilkunnil T., He H., Kong D., Asakura K., Peroni O.D., Lee A., et al. Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo. J. Biol. Chem. 2011, 286:8798-8809.
156. Hutchinson D.S., Bengtsson T. AMP-activated protein kinase activation by adrenoceptors in L6 skeletal muscle cells: mediation by alpha1-adrenoceptors causing glucose uptake. Diabetes 2006, 55:682-690.
157. Ma L., Gul R., Habibi J., Yang M., Pulakat L., Whaley-Connell A., et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H2341-H2351.
158. Zhou X., Ma L., Habibi J., Whaley-Connell A., Hayden M.R., Tilmon R.D., et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension 2010, 55:880-888.
159. Sorrentino S.A., Doerries C., Manes C., Speer T., Dessy C., Lobysheva I., et al. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional beta1-blockade. J. Am. Coll. Cardiol. 2011, 57:601-611.
160. Vilahur G., Casani L., Pena E., Juan-Babot O., Mendieta G., Crespo J., et al. HMG-CoA reductase inhibition prior reperfusion improves reparative fibrosis post-myocardial infarction in a preclinical experimental model. Int. J. Cardiol. 2014, 175:528-538.
161. Patel R., Nagueh S.F., Tsybouleva N., Abdellatif M., Lutucuta S., Kopelen H.A., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001, 104:317-324.
162. Sun W., Lee T.S., Zhu M., Gu C., Wang Y., Zhu Y., et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006, 114:2655-2662.
163. Izumi Y., Shiota M., Kusakabe H., Hikita Y., Nakao T., Nakamura Y., et al. Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. Hypertens. Res. 2009, 32:675-679.
164. Javaux F., Vincent M.F., Wagner D.R., van den Berghe G. Cell-type specificity of inhibition of glycolysis by 5-amino-4-imidazolecarboxamide riboside. Lack of effect in rabbit cardiomyocytes and human erythrocytes, and inhibition in FTO-2B rat hepatoma cells. Biochem. J. 1995, 305(Pt 3):913-919.
165. Chen K.H., Hsu H.H., Lee C.C., Yen T.H., Ko Y.C., Yang C.W., et al. The AMPK agonist AICAR inhibits TGF-beta1 induced activation of kidney myofibroblasts. PLoS ONE 2014, 9.
166. Goransson O., McBride A., Hawley S.A., Ross F.A., Shpiro N., Foretz M., et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem. 2007, 282:32549-32560.
167. Paiva M.A., Rutter-Locher Z., Goncalves L.M., Providencia L.A., Davidson S.M., Yellon D.M., et al. Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H2123-H2134.
168. Ducommun S., Ford R.J., Bultot L., Deak M., Bertrand L., Kemp B.E., et al. Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662. Am. J. Physiol. Endocrinol. Metab. 2014, 306:E688-E696.
169. Li Y.Y., Yu L.F., Zhang L.N., Qiu B.Y., Su M.B., Wu F., et al. Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice. Toxicol. Appl. Pharmacol. 2013, 273:325-334.
170. Shibata R., Ouchi N., Ito M., Kihara S., Shiojima I., Pimentel D.R., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 2004, 10:1384-1389.
171. Dadson K., Chasiotis H., Wannaiampikul S., Tungtrongchitr R., Xu A., Sweeney G. Adiponectin mediated APPL1-AMPK signaling induces cell migration, MMP activation, and collagen remodeling in cardiac fibroblasts. J. Cell. Biochem. 2014, 115:785-793.
172. Shimano M., Ouchi N., Shibata R., Ohashi K., Pimentel D.R., Murohara T., et al. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J. Mol. Cell. Cardiol. 2010, 49:210-220.
173. Konishi M., Haraguchi G., Ohigashi H., Ishihara T., Saito K., Nakano Y., et al. Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc. Res. 2011, 89:309-319.
174. Hu N., Yang L., Dong M., Ren J., Zhang Y. Deficiency in adiponectin exaggerates cigarette smoking exposure-induced cardiac contractile dysfunction: role of autophagy. Pharmacol. Res. 2015, 100:175-189.
175. Zhang Y., Zhao J., Li R., Lau W.B., Yuan Y.X., Liang B., et al. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am. J. Physiol. Endocrinol. Metab. 2015, 309:E275-E282.
176. Sung M.M., Dyck J.R. Therapeutic potential of resveratrol in heart failure. Ann. N. Y. Acad. Sci. 2015, 1348:32-45.
177. Olson E.R., Naugle J.E., Zhang X., Bomser J.A., Meszaros J.G. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H1131-H1138.
178. Sin T.K., Yu A.P., Yung B.Y., Yip S.P., Chan L.W., Wong C.S., et al. Modulating effect of SIRT1 activation induced by resveratrol on Foxo1-associated apoptotic signalling in senescent heart. J. Physiol. 2014, 592:2535-2548.
179. Chen T., Li J., Liu J., Li N., Wang S., Liu H., et al. Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-beta/Smad3 pathway. Am. J. Physiol. Heart Circ. Physiol. 2015, 308:H424-H434.
180. Price N.L., Gomes A.P., Ling A.J., Duarte F.V., Martin-Montalvo A., North B.J., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012, 15:675-690.
181. Pillai V.B., Sundaresan N.R., Kim G., Gupta M., Rajamohan S.B., Pillai J.B., et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J. Biol. Chem. 2010, 285:3133-3144.
182. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
183. Um J.H., Park S.J., Kang H., Yang S., Foretz M., McBurney M.W., et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59:554-563.
184. Arafa M.H., Mohammad N.S., Atteia H.H., Abd-Elaziz H.R. Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J. Physiol. Biochem. 2014, 70:701-711.
185. Gupta P.K., DiPette D.J., Supowit S.C. Protective effect of resveratrol against pressure overload-induced heart failure. Food Sci. Nutri. 2014, 2:218-229.
186. Dong Q., Wu Z., Li X., Yan J., Zhao L., Yang C., et al. Resveratrol ameliorates cardiac dysfunction induced by pressure overload in rats via structural protection and modulation of Ca(2+) cycling proteins. J. Transl. Med. 2014, 12:323.
187. Lei H., Wu D., Wang J.Y., Li L., Zhang C.L., Feng H., et al. C1q/tumor necrosis factor-related protein-6 attenuates post-infarct cardiac fibrosis by targeting RhoA/MRTF-A pathway and inhibiting myofibroblast differentiation. Basic Res. Cardiol. 2015, 110:35.
188. Sun Y., Yi W., Yuan Y., Lau W.B., Yi D., Wang X., et al. C1q/tumor necrosis factor-related protein-9, a novel adipocyte-derived cytokine, attenuates adverse remodeling in the ischemic mouse heart via protein kinase A activation. Circulation 2013, 128:S113-S120.
189. Deng W., Zong J., Bian Z., Zhou H., Yuan Y., Zhang R., et al. Indole-3-carbinol protects against pressure overload induced cardiac remodeling via activating AMPK-alpha. Mol. Nutr. Food Res. 2013, 57:1680-1687.
190. Matsuo K., Shibata R., Ohashi K., Kambara T., Uemura Y., Hiramatsu-Ito M., et al. Omentin functions to attenuate cardiac hypertrophic response. J. Mol. Cell. Cardiol. 2015, 79:195-202.
191. Vilahur G., Casani L., Guerra J.M., Badimon L. Intake of fermented beverages protect against acute myocardial injury: target organ cardiac effects and vasculoprotective effects. Basic Res. Cardiol. 2012, 107:291.
192. Schisler J.C., Rubel C.E., Zhang C., Lockyer P., Cyr D.M., Patterson C. CHIP protects against cardiac pressure overload through regulation of AMPK. J. Clin. Invest. 2013, 123:3588-3599.
193. Kim J., Lee K.M., Park C.S., Park W.J. Ablation of cereblon attenuates myocardial ischemia-reperfusion injury. Biochem. Biophys. Res. Commun. 2014, 447:649-654.
194. Plante E., Menaouar A., Danalache B.A., Broderick T.L., Jankowski M., Gutkowska J. Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice. Diabetologia 2014, 57:1257-1267.
195. Pei X.M., Yung B.Y., Yip S.P., Chan L.W., Wong C.S., Ying M., et al. Protective effects of desacyl ghrelin on diabetic cardiomyopathy. Acta Diabetol. 2015, 52:293-306.
196. Zhang Z., Wang S., Zhou S., Yan X., Wang Y., Chen J., et al. Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway. J. Mol. Cell. Cardiol. 2014, 77:42-52.
197. McGaffin K.R., Witham W.G., Yester K.A., Romano L.C., O'Doherty R.M., McTiernan C.F., et al. Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice. Cardiovasc. Res. 2011, 89:60-71.
198. Zhao Y., Tan Y., Xi S., Li Y., Li C., Cui J., et al. A novel mechanism by which SDF-1beta protects cardiac cells from palmitate-induced endoplasmic reticulum stress and apoptosis via CXCR7 and AMPK/p38 MAPK-mediated interleukin-6 generation. Diabetes 2013, 62:2545-2558.
199. Shimano M., Ouchi N., Nakamura K., van Wijk B., Ohashi K., Asaumi Y., et al. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E899-E906.
200. Xu X., Hua Y., Nair S., Bucala R., Ren J. Macrophage migration inhibitory factor deletion exacerbates pressure overload-induced cardiac hypertrophy through mitigating autophagy. Hypertension 2014, 63:490-499.
201. Giordanetto F., Karis D. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature. Expert Opin. Ther. Pat. 2012, 22:1467-1477.
202. Zou M.H., Xie Z. Regulation of interplay between autophagy and apoptosis in the diabetic heart: new role of AMPK. Autophagy 2013, 9:624-625.